1 Introduction to Research & Analysis Reports
1.1 Non-melanoma Skin Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Non-melanoma Skin Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Non-melanoma Skin Cancer Drugs Overall Market Size
2.1 Global Non-melanoma Skin Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Non-melanoma Skin Cancer Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Non-melanoma Skin Cancer Drugs Players in Global Market
3.2 Top Global Non-melanoma Skin Cancer Drugs Companies Ranked by Revenue
3.3 Global Non-melanoma Skin Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Non-melanoma Skin Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Non-melanoma Skin Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Non-melanoma Skin Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Non-melanoma Skin Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Non-melanoma Skin Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Non-melanoma Skin Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Imiquimod Cream
4.1.3 5-fluorouracil Cream
4.1.4 Vismodegib
4.1.5 Cemiplimab
4.1.6 Cisplatin
4.1.7 Paclitaxel
4.2 By Type – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
4.2.1 By Type – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
4.2.2 By Type – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
4.2.3 By Type – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Non-melanoma Skin Cancer Drugs Market Size, 2022 & 2029
5.1.2 Basal Cell Carcinoma (BCC)
5.1.3 Squamous Cell Carcinoma (SCC)
5.2 By Application – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
5.2.1 By Application – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
5.2.2 By Application – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
5.2.3 By Application – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Non-melanoma Skin Cancer Drugs Market Size, 2022 & 2029
6.2 By Region – Global Non-melanoma Skin Cancer Drugs Revenue & Forecasts
6.2.1 By Region – Global Non-melanoma Skin Cancer Drugs Revenue, 2018-2023
6.2.2 By Region – Global Non-melanoma Skin Cancer Drugs Revenue, 2024-2029
6.2.3 By Region – Global Non-melanoma Skin Cancer Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.3.2 US Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.3.3 Canada Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.3.4 Mexico Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.4.2 Germany Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.3 France Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.4 U.K. Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.5 Italy Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.6 Russia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.4.8 Benelux Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.5.2 China Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.3 Japan Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.4 South Korea Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.5.6 India Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.6.2 Brazil Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.6.3 Argentina Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Non-melanoma Skin Cancer Drugs Revenue, 2018-2029
6.7.2 Turkey Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.3 Israel Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
6.7.5 UAE Non-melanoma Skin Cancer Drugs Market Size, 2018-2029
7 Non-melanoma Skin Cancer Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Non-melanoma Skin Cancer Drugs Major Product Offerings
7.1.4 Pfizer Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Bausch Health
7.2.1 Bausch Health Company Summary
7.2.2 Bausch Health Business Overview
7.2.3 Bausch Health Non-melanoma Skin Cancer Drugs Major Product Offerings
7.2.4 Bausch Health Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 Bausch Health Key News & Latest Developments
7.3 Mayne Pharma
7.3.1 Mayne Pharma Company Summary
7.3.2 Mayne Pharma Business Overview
7.3.3 Mayne Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.3.4 Mayne Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Mayne Pharma Key News & Latest Developments
7.4 Roche
7.4.1 Roche Company Summary
7.4.2 Roche Business Overview
7.4.3 Roche Non-melanoma Skin Cancer Drugs Major Product Offerings
7.4.4 Roche Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 Roche Key News & Latest Developments
7.5 United Laboratories
7.5.1 United Laboratories Company Summary
7.5.2 United Laboratories Business Overview
7.5.3 United Laboratories Non-melanoma Skin Cancer Drugs Major Product Offerings
7.5.4 United Laboratories Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 United Laboratories Key News & Latest Developments
7.6 3M
7.6.1 3M Company Summary
7.6.2 3M Business Overview
7.6.3 3M Non-melanoma Skin Cancer Drugs Major Product Offerings
7.6.4 3M Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.6.5 3M Key News & Latest Developments
7.7 Perrigo
7.7.1 Perrigo Company Summary
7.7.2 Perrigo Business Overview
7.7.3 Perrigo Non-melanoma Skin Cancer Drugs Major Product Offerings
7.7.4 Perrigo Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.7.5 Perrigo Key News & Latest Developments
7.8 Biological E.
7.8.1 Biological E. Company Summary
7.8.2 Biological E. Business Overview
7.8.3 Biological E. Non-melanoma Skin Cancer Drugs Major Product Offerings
7.8.4 Biological E. Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.8.5 Biological E. Key News & Latest Developments
7.9 Glenmark Pharmaceuticals
7.9.1 Glenmark Pharmaceuticals Company Summary
7.9.2 Glenmark Pharmaceuticals Business Overview
7.9.3 Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Major Product Offerings
7.9.4 Glenmark Pharmaceuticals Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.9.5 Glenmark Pharmaceuticals Key News & Latest Developments
7.10 Sichuan Med-shine Pharmaceutical
7.10.1 Sichuan Med-shine Pharmaceutical Company Summary
7.10.2 Sichuan Med-shine Pharmaceutical Business Overview
7.10.3 Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.10.4 Sichuan Med-shine Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.10.5 Sichuan Med-shine Pharmaceutical Key News & Latest Developments
7.11 Henan Topfond Pharmaceutical
7.11.1 Henan Topfond Pharmaceutical Company Summary
7.11.2 Henan Topfond Pharmaceutical Business Overview
7.11.3 Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.11.4 Henan Topfond Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.11.5 Henan Topfond Pharmaceutical Key News & Latest Developments
7.12 Regeneron (Sanofi)
7.12.1 Regeneron (Sanofi) Company Summary
7.12.2 Regeneron (Sanofi) Business Overview
7.12.3 Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Major Product Offerings
7.12.4 Regeneron (Sanofi) Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.12.5 Regeneron (Sanofi) Key News & Latest Developments
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Company Summary
7.13.2 Bristol-Myers Squibb Business Overview
7.13.3 Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Major Product Offerings
7.13.4 Bristol-Myers Squibb Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.13.5 Bristol-Myers Squibb Key News & Latest Developments
7.14 Sun Pharma
7.14.1 Sun Pharma Company Summary
7.14.2 Sun Pharma Business Overview
7.14.3 Sun Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.14.4 Sun Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.14.5 Sun Pharma Key News & Latest Developments
7.15 Qilu Pharmaceutical
7.15.1 Qilu Pharmaceutical Company Summary
7.15.2 Qilu Pharmaceutical Business Overview
7.15.3 Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Major Product Offerings
7.15.4 Qilu Pharmaceutical Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.15.5 Qilu Pharmaceutical Key News & Latest Developments
7.16 Hansoh Pharma
7.16.1 Hansoh Pharma Company Summary
7.16.2 Hansoh Pharma Business Overview
7.16.3 Hansoh Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.16.4 Hansoh Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.16.5 Hansoh Pharma Key News & Latest Developments
7.17 Celgene Corporation
7.17.1 Celgene Corporation Company Summary
7.17.2 Celgene Corporation Business Overview
7.17.3 Celgene Corporation Non-melanoma Skin Cancer Drugs Major Product Offerings
7.17.4 Celgene Corporation Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.17.5 Celgene Corporation Key News & Latest Developments
7.18 Taj Accura
7.18.1 Taj Accura Company Summary
7.18.2 Taj Accura Business Overview
7.18.3 Taj Accura Non-melanoma Skin Cancer Drugs Major Product Offerings
7.18.4 Taj Accura Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.18.5 Taj Accura Key News & Latest Developments
7.19 Khandelwal Laboratories Pvt Ltd.
7.19.1 Khandelwal Laboratories Pvt Ltd. Company Summary
7.19.2 Khandelwal Laboratories Pvt Ltd. Business Overview
7.19.3 Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Major Product Offerings
7.19.4 Khandelwal Laboratories Pvt Ltd. Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.19.5 Khandelwal Laboratories Pvt Ltd. Key News & Latest Developments
7.20 Luye Pharma
7.20.1 Luye Pharma Company Summary
7.20.2 Luye Pharma Business Overview
7.20.3 Luye Pharma Non-melanoma Skin Cancer Drugs Major Product Offerings
7.20.4 Luye Pharma Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.20.5 Luye Pharma Key News & Latest Developments
7.21 Beijing Youcare
7.21.1 Beijing Youcare Company Summary
7.21.2 Beijing Youcare Business Overview
7.21.3 Beijing Youcare Non-melanoma Skin Cancer Drugs Major Product Offerings
7.21.4 Beijing Youcare Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.21.5 Beijing Youcare Key News & Latest Developments
7.22 Beijing Union Pharmaceutical Factory
7.22.1 Beijing Union Pharmaceutical Factory Company Summary
7.22.2 Beijing Union Pharmaceutical Factory Business Overview
7.22.3 Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Major Product Offerings
7.22.4 Beijing Union Pharmaceutical Factory Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.22.5 Beijing Union Pharmaceutical Factory Key News & Latest Developments
7.23 Hainan Haiyao
7.23.1 Hainan Haiyao Company Summary
7.23.2 Hainan Haiyao Business Overview
7.23.3 Hainan Haiyao Non-melanoma Skin Cancer Drugs Major Product Offerings
7.23.4 Hainan Haiyao Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.23.5 Hainan Haiyao Key News & Latest Developments
7.24 Chuntch
7.24.1 Chuntch Company Summary
7.24.2 Chuntch Business Overview
7.24.3 Chuntch Non-melanoma Skin Cancer Drugs Major Product Offerings
7.24.4 Chuntch Non-melanoma Skin Cancer Drugs Revenue in Global Market (2018-2023)
7.24.5 Chuntch Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
世界の非メラノーマ皮膚がん治療薬市場予測2023-2029：イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル |
| 【英語タイトル】Non-melanoma Skin Cancer Drugs Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5811 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：110 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の非メラノーマ皮膚がん治療薬市場規模と予測を収録しています。・世界の非メラノーマ皮膚がん治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の非メラノーマ皮膚がん治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の非メラノーマ皮膚がん治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「イミキモドクリーム」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 非メラノーマ皮膚がん治療薬のグローバル主要企業は、Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntchなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、非メラノーマ皮膚がん治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の非メラノーマ皮膚がん治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の非メラノーマ皮膚がん治療薬市場：タイプ別市場シェア、2022年 ・イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル 世界の非メラノーマ皮膚がん治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の非メラノーマ皮膚がん治療薬市場：用途別市場シェア、2022年 ・基底細胞癌（BCC）、扁平上皮癌（SCC） 世界の非メラノーマ皮膚がん治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の非メラノーマ皮膚がん治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における非メラノーマ皮膚がん治療薬のグローバル売上、2018年-2023年 ・主要企業における非メラノーマ皮膚がん治療薬のグローバル売上シェア、2022年 ・主要企業における非メラノーマ皮膚がん治療薬のグローバル販売量、2018年-2023年 ・主要企業における非メラノーマ皮膚がん治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntch ************************************************************* ・調査・分析レポートの概要 非メラノーマ皮膚がん治療薬市場の定義 市場セグメント 世界の非メラノーマ皮膚がん治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の非メラノーマ皮膚がん治療薬市場規模 世界の非メラノーマ皮膚がん治療薬市場規模：2022年 VS 2029年 世界の非メラノーマ皮膚がん治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの非メラノーマ皮膚がん治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の非メラノーマ皮膚がん治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル 非メラノーマ皮膚がん治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：基底細胞癌（BCC）、扁平上皮癌（SCC） 非メラノーマ皮膚がん治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別非メラノーマ皮膚がん治療薬市場規模 2022年と2029年 地域別非メラノーマ皮膚がん治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Pfizer、 Bausch Health、 Mayne Pharma、 Roche、 United Laboratories、 3M、 Perrigo、 Biological E.、 Glenmark Pharmaceuticals、 Sichuan Med-shine Pharmaceutical、 Henan Topfond Pharmaceutical、 Regeneron (Sanofi)、 Bristol-Myers Squibb、 Sun Pharma、 Qilu Pharmaceutical、 Hansoh Pharma、 Celgene Corporation、 Taj Accura、 Khandelwal Laboratories Pvt Ltd.、 Luye Pharma、 Beijing Youcare、 Beijing Union Pharmaceutical Factory、 Hainan Haiyao、 Chuntch ... |
This report aims to provide a comprehensive presentation of the global market for Non-melanoma Skin Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-melanoma Skin Cancer Drugs. This report contains market size and forecasts of Non-melanoma Skin Cancer Drugs in global, including the following market information:
Global Non-melanoma Skin Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-melanoma Skin Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Imiquimod Cream Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-melanoma Skin Cancer Drugs include Pfizer, Bausch Health, Mayne Pharma, Roche, United Laboratories, 3M, Perrigo, Biological E. and Glenmark Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Non-melanoma Skin Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-melanoma Skin Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
Imiquimod Cream
5-fluorouracil Cream
Vismodegib
Cemiplimab
Cisplatin
Paclitaxel
Global Non-melanoma Skin Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
Basal Cell Carcinoma (BCC)
Squamous Cell Carcinoma (SCC)
Global Non-melanoma Skin Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-melanoma Skin Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-melanoma Skin Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-melanoma Skin Cancer Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Bausch Health
Mayne Pharma
Roche
United Laboratories
3M
Perrigo
Biological E.
Glenmark Pharmaceuticals
Sichuan Med-shine Pharmaceutical
Henan Topfond Pharmaceutical
Regeneron (Sanofi)
Bristol-Myers Squibb
Sun Pharma
Qilu Pharmaceutical
Hansoh Pharma
Celgene Corporation
Taj Accura
Khandelwal Laboratories Pvt Ltd.
Luye Pharma
Beijing Youcare
Beijing Union Pharmaceutical Factory
Hainan Haiyao
Chuntch
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-melanoma Skin Cancer Drugs, market overview.
Chapter 2: Global Non-melanoma Skin Cancer Drugs market size in revenue.
Chapter 3: Detailed analysis of Non-melanoma Skin Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-melanoma Skin Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の非メラノーマ皮膚がん治療薬市場予測2023-2029：イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル] (コード：MMG23JU5811)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の非メラノーマ皮膚がん治療薬市場予測2023-2029：イミキモドクリーム、5-フルオロウラシルクリーム、ビスモデギブ、セミプリマブ、シスプラチン、パクリタキセル]についてメールでお問い合わせ |
